<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180213038710N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-09-10</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>The effectiveness of implementation of Rehacom Cognitive Rehabilitation Therapy on cognitive function of the elderly with normal cognition, MCI and mild Alzheimer: A pilot study</public_title>
      <acronym></acronym>
      <scientific_title>The effectiveness of the implementation of Rehacom Cognitive Rehabilitation Therapy on cognitive function of the elderly with normal cognition, MCI, and mild Alzheimer: A pilot study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>72</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/72412</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: In order to evenly distribute people based on their cognitive status into two intervention and control groups; the participants will be divided into three groups based on the scores obtained from the MoCA form, the elderly with normal cognitive status and the elderly with mild cognitive impairment (MCI) and elderly with mild Alzheimer's will be randomly assigned in two intervention and control groups. The random assignment of the elderly will be done based on the cognitive and educational status of the elderly.
The Stratified random block method will be done based on education level (diploma, Associate/Bachelor degree, Master's degree or higher) and cognitive status (normal, MCI, mild Alzheimer's) and participants allocated to intervention and control groups. Based on education level and cognitive status, 6 stratifications will be formed.
Within each stratify; the method of random blocks of 6 will be used to assign participants to two groups A (intervention) and group B (control). For this, the list of blocks is first written and numbers are assigned to them AABB(1)- ABAB(2)-ABBA(3)-BBAA(4) and the order of these blocks will be determined randomly by Excell software, Blinding description: This study will be a single-blinded randomized clinical trial. Therefore, the participants of the study will not be informed from the study groups (intervention-control). For this purpose, sampling of the participants in the intervention and control groups will be done from different centers in the city. The possibility of blinding the researcher is not possible due to the mastery of Rehacom evaluation software.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Alzheimer.</hc_freetext>
      <i_freetext>Intervention 1: "Intervention group" (recipient of cognitive rehabilitation based on Rehacom software): In the intervention group, the rehabilitation program for the intervention group will be implemented individually for 16 sessions of 45 minutes twice a week. Based on the Rehacom platform, the areas of self-awareness, orientation, attention, visual processing, motor vision, motor planning, memory, organization, and problem-solving can be trained. However, each session focuses on the cognitive deficit of different domains. The method of performing each of these tasks will be explained by the researcher for better comprehension of instruction for the elderly. The program of each session will be different from the previous session, which will motivate the subjects to continue the treatment. Intervention 2: "Control group": In the control group, The Rehacom evaluation will be performed before the intervention (at the beginning of the study) and after the intervention period, will be done in the elderly in the control group. These people will carry out their normal life routines and will not receive any rehabilitation intervention.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Considering that part of the information is related to the elderly with mild Alzheimer's and MCI, the research team prefers that the information is not available to other people except the research team.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maryam Chehregosha</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Falsafi Educational Campus, Shastkola Road, Hirkan Blvd. Golestan University of Medical Sciences</address>
        <city>Gorgan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4918936316</zip>
        <telephone>+98 17 3245 6102</telephone>
        <email>Chehrehgosha@goums.ac.ir</email>
        <affiliation>Gorgan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Maryam Chehrehgosha</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Falsafi Educational Campus, Shastkola Road, Hirkan Blvd. Golestan University of Medical Sciences</address>
        <city>Gorgan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4918936316</zip>
        <telephone>+98 17 3243 0319</telephone>
        <email>cherehgosha@goums.ac.ir</email>
        <affiliation>Gorgan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Being older than 65 years
Literate person (having at least diploma)
Obtaining a score of 11 and greater on the MoCA
Obtaining a score of less than 8 on the GDS-15 (Geriatric Depression Scale-15)
Ability to speak Persian
Having a personal desire to participate in the study
Having no epilepsy, vision problems, hearing, or severe disabilities
Having aformal or informal caregiver</inclusion_criteria>
      <agemin>65 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Inability to continue participating for any reason
Failure to attend two consecutive or alternating sessions</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G30.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Alzheimer's disease with late onset</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>"Intervention group" (recipient of cognitive rehabilitation based on Rehacom software): In the intervention group, the rehabilitation program for the intervention group will be implemented individually for 16 sessions of 45 minutes twice a week. Based on the Rehacom platform, the areas of self-awareness, orientation, attention, visual processing, motor vision, motor planning, memory, organization, and problem-solving can be trained. However, each session focuses on the cognitive deficit of different domains. The method of performing each of these tasks will be explained by the researcher for better comprehension of instruction for the elderly. The program of each session will be different from the previous session, which will motivate the subjects to continue the treatment.</i_keyword>
      <i_keyword>"Control group": In the control group, The Rehacom evaluation will be performed before the intervention (at the beginning of the study) and after the intervention period, will be done in the elderly in the control group. These people will carry out their normal life routines and will not receive any rehabilitation intervention.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Processing speed of cognitive tests based on Rehacom. Timepoint: In the intervention group at the beginning of the study, in each treatment session, at the end of the intervention/in the control group at the beginning of the study and at the end of the study. Method of measurement: Rehacom software measures these variables.</prim_outcome>
      <prim_outcome>The difficulty level of the test. Timepoint: In the intervention group at the beginning of the study, in each treatment session, at the end of the intervention/in the control group at the beginning of the study and at the end of the study. Method of measurement: Rehacom software measures these variables.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Cognitive status based on MoCA score. Timepoint: In the intervention group at the beginning of the study, in each treatment session, at the end of the intervention/in the control group at the beginning of the study and at the end of the study. Method of measurement: Rehacom software measures these variables.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-08-28</approval_date>
        <contact_name>Ethics committee  of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Central Building of Tabriz University of Medical Sciences, Golgasht Street, Tabriz, Iran Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
